Aliases: | 16.3A5, 1F5, EJ16, EJ30, EL32, G344, HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, p18-20 |
---|---|
Other: | CD59 glycoprotein|1F5 antigen|20 kDa homologous restriction factor|CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)|CD59 blood group antigen|CD59 molecule, complement regulatory protein|Ly-6-like protein|MEM43 antigen|T cell-activating protein|human leukocyte antigen MIC11|lymphocytic antigen CD59/MEM43|membrane attack complex (MAC) inhibition factor|membrane attack complex inhibition factor|membrane inhibitor of reactive lysis|protectin|surface anitgen recognized by monoclonal antibody 16.3A5 |
This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is neces... see more
Brilliant Violet 711
Common Laser: | 405 |
---|---|
Common Filter: | 710/50 |
Excitation Peak: | 405 |
Emission Peak: | 711 |
Brilliant™ Violet 711 (BV711) is a red-emitting tandem fluorophore that can be excited by the 405 nm Violet laser and collected using a 710/50 bandpass filter. BV711 has an excitation peak at 405 nm and an emission peak at 711 nm. BV711 exhibits a medium level of brightness and is most often used in flow cytometry, specifically, it is an alternative to nanocrystals used for intracellular flow... see more
Popular CD59 Brilliant Violet 711 Antibodies
Company / SKU |
Applications | Marker / Reactivity |
Host / Isotype / Clone |
Size / Price |
Details | |
---|---|---|---|---|---|---|
BD Biosciences 742939 |
FC | CD59 Human |
Mouse IgG2a κ p282 (H19) |
50 μg $495 |
Details | |
BD Biosciences 742619 |
FC | CD59 Rat |
Mouse IgG1 κ TH9 |
50 μg $350 |
Details | |
Browse CD59 / Brilliant Violet 711 antibodies. |